Sonnet BioTherapeutics Holdings, Inc.
(NASDAQ : SONN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. 0.94%245.371.5%$940.74m
MRNAModerna, Inc. 0.71%144.270.0%$849.73m
REGNRegeneron Pharmaceuticals, Inc. 0.84%612.492.6%$526.18m
VRTXVertex Pharmaceuticals, Inc. 3.19%292.551.9%$516.29m
GILDGilead Sciences, Inc. 0.80%63.081.0%$513.27m
NVAXNovavax, Inc. -0.27%51.6775.7%$422.21m
ILMNIllumina, Inc. 0.20%193.933.3%$361.41m
BIIBBiogen, Inc. 0.26%211.931.8%$242.32m
SNSSSunesis Pharmaceuticals, Inc. 9.63%2.960.7%$206.91m
CRSPCRISPR Therapeutics AG 2.78%66.960.6%$173.29m
BNTXBioNTech SE 1.32%134.040.0%$153.17m
BMRNBioMarin Pharmaceutical, Inc. 2.72%86.854.2%$121.28m
EXASEXACT Sciences Corp. 6.89%45.1517.7%$107.32m
IOVAIovance Biotherapeutics, Inc. 0.19%10.350.0%$103.94m
TECHBio-Techne Corp. 2.16%352.764.5%$95.22m

Company Profile

Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its pipeline focuses on cytokines, a class of cell signaling peptides that, among other important functions, serve as potent immunomodulatory agents. The company was founded in 2011 and is headquartered in Princeton, NJ.